PledPharma (Sweden)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 7 of 7 papers

  • Open Access
  • Research Article
  • Citations18

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale

  • Feb 15, 2020
  • World Journal of Gastrointestinal Oncology
  • Karen Kaiser +7
  • Open Access
  • Research Article
  • Citations60

Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.

  • Jan 01, 2020
  • Journal of Parkinson's Disease
  • C Warren Olanow +10
  • Research Article
  • Citations3

Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).

  • May 20, 2016
  • Journal of Clinical Oncology
  • Bengt Glimelius +8
  • Research Article

Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study (P5.372)

  • Apr 05, 2016
  • Neurology
  • Peter Lewitt +4
  • Research Article
  • Citations2

Anti-inflammatory treatment of traumatic brain injury with Rabeximod reduces cerebral antigen presentation in mice.

  • Jun 10, 2015
  • Journal of Neuroscience Research
  • Charlotte Israelsson +3
  • Open Access
  • Front Matter

Breaking away from the norm: a new perspective on cancer therapeutics

  • Aug 09, 2014
  • Drug Discovery Today
  • Jacques Näsström
  • Abstract
  • Citations2

OP0061 Kineret® (Anakinra) Controls Disease Symptoms in Patients with Severe Cryopyrin-Associated Periodic Syndromes (CAPS): Up to 5-Year Follow-Up Data

  • Jun 01, 2013
  • Annals of the Rheumatic Diseases
  • H Olivecrona +17
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.